Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Antibody fragments are recognized as promising vehicles for delivery of imaging and therapeutic agents to tumor sites in vivo. The serum persistence of IgG1 and fragments with intact Fc region is controlled by the protective neonatal Fc receptor (FcRn) receptor. To modulate the half-life of engineered antibodies, we have mutated the Fc-FcRn binding site of chimeric anti-carcinoembryonic antigen (CEA) antibodies produced in a single-chain Fv-Fc format. The anti-CEA T84.66 single-chain Fv-Fc format wild-type and five mutants (I253A, H310A, H435Q, H435R, and H310A/H435Q, Kabat numbering system) expressed well in mammalian cell culture. After purification and characterization, effective in vitro antigen binding was shown by competition ELISA. Biodistribution studies in BALB/c mice using (125)I- and (131)I-labeled fragments revealed blood clearance rates from slowest to fastest as follows: wild-type > H435R > H435Q > I253A > H310A > H310A/H435Q. The terminal half-lives of the mutants ranged from 83.4 to 7.96 hours, whereas that of the wild-type was approximately 12 days. Additionally, (124)I-labeled wild-type, H435Q, I253A, H310A, and H310A/H435Q variants were evaluated in LS174T xenografted athymic mice by small animal positron emission tomography imaging, revealing localization to the CEA-positive xenografts. The slow clearing wild-type and H435Q constructs required longer to localize to the tumor and clear from the circulation. The I253A and H310A fragments showed intermediate behavior, whereas the H310A/H435Q variant quickly localized to the tumor site, rapidly cleared from the animal circulation and produced clear images. Thus, attenuating the Fc-FcRn interaction provides a way of controlling the antibody fragment serum half-life without compromising expression and tumor targeting.

[1]  J. Tso,et al.  Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates* , 2004, Journal of Biological Chemistry.

[2]  S. Gambhir,et al.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.

[3]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Raimund J Ober,et al.  Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. , 2003, Journal of molecular biology.

[5]  Sanjiv Sam Gambhir,et al.  AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.

[6]  E. Choi,et al.  The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs1 , 2003, The Journal of Immunology.

[7]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[8]  A A Raubitschek,et al.  Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. , 2001, Journal of immunological methods.

[9]  A. West,et al.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. , 2001, Molecular cell.

[10]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[11]  J. Wong,et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.

[12]  L E Williams,et al.  Numerical selection of optimal tumor imaging agents with application to engineered antibodies. , 2001, Cancer biotherapy & radiopharmaceuticals.

[13]  A. Wu,et al.  Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[14]  A. West,et al.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). , 2000, Biochemistry.

[15]  Y. Shyr,et al.  Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. , 2000, Cancer research.

[16]  L. Khawli,et al.  Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  E. Ward,et al.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.

[18]  Jin‐Kyoo Kim,et al.  Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn , 1999, European journal of immunology.

[19]  Raimund J. Ober,et al.  Increasing the serum persistence of an IgG fragment by random mutagenesis , 1997, Nature Biotechnology.

[20]  Michel Defrise,et al.  Exact and approximate rebinning algorithms for 3-D PET data , 1997, IEEE Transactions on Medical Imaging.

[21]  E. Ward,et al.  Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. , 1997, Journal of immunology.

[22]  R. Junghans.  Finally! the Brambell receptor (FcRB) , 1997, Immunologic research.

[23]  D. Schoenfeld,et al.  Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn , 1996, Immunology.

[24]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[25]  C. Anderson,et al.  The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jin‐Kyoo Kim,et al.  Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice , 1996, European journal of immunology.

[27]  P. Hand,et al.  Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. , 1995, Cancer research.

[28]  E. Ward,et al.  Catabolism of the Murine IgGl Molecule: Evidence that Both CH2‐CH3 Domain Interfaces are Required for Persistence of IgGl in the Circulation of Mice , 1994 .

[29]  E. Ward,et al.  Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. , 1994, Scandinavian journal of immunology.

[30]  N. Copeland,et al.  Mouse MHC class I-like Fc receptor encoded outside the MHC. , 1993, Journal of immunology.

[31]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.

[32]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[33]  A. Riggs,et al.  Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. , 1990, Cancer research.

[34]  K. Mostov,et al.  An Fc receptor structurally related to MHC class I antigens , 1989, Nature.

[35]  A. Rees,et al.  Isolation and characterization of an Fc receptor from neonatal rat small intestine , 1985, European journal of immunology.

[36]  J. Deisenhofer.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[37]  C. Milstein,et al.  [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .

[38]  C. Milstein,et al.  Preparation of monoclonal antibodies: strategies and procedures. , 1981, Methods in enzymology.

[39]  L. Benet,et al.  Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.

[40]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[41]  R. Rodewald.  pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat , 1976, The Journal of cell biology.

[42]  R. Rodewald.  SELECTIVE ANTIBODY TRANSPORT IN THE PROXIMAL SMALL INTESTINE OF THE NEONATAL RAT , 1970, The Journal of cell biology.

[43]  T. Waldmann,et al.  Metabolism of immunoglobulins. , 1969, Progress in allergy.

[44]  F. W. Brambell.  The transmission of immunity from mother to young and the catabolism of immunoglobulins. , 1966, Lancet.

[45]  R. Halliday,et al.  Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice , 1958, Proceedings of the Royal Society of London. Series B - Biological Sciences.